Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Rhea-AI Summary

Jyong Biotech (NASDAQ:MENS) has received the Innovation Gold Award at the 2025 Taipei Biotech Awards for its oral plant-derived drug BOTRESO®, designed to treat benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS). The award includes a $26,000 cash prize.

BOTRESO®, developed by subsidiary Health Ever Bio-Tech Co., holds multiple worldwide patents and has completed four Phase III clinical trials in the US and Taiwan. The drug represents the first Taiwan-developed oral botanical drug to receive FDA IND approval and advance to Phase III trials. The company has submitted a New Drug Application (NDA) to the U.S. FDA.

Positive

• First Taiwan-developed oral botanical drug to receive FDA IND approval and reach Phase III trials
• Successful completion of four Phase III clinical trials in US and Taiwan
• NDA submission to U.S. FDA completed
• Multiple worldwide patents secured for BOTRESO®

Negative

• None.

News Market Reaction – MENS

-16.30% 1.9x vol

21 alerts

-16.30% News Effect

-31.0% Trough in 25 hr 41 min

-$846M Valuation Impact

$4.34B Market Cap

1.9x Rel. Volume

On the day this news was published, MENS declined 16.30%, reflecting a significant negative market reaction. Argus tracked a trough of -31.0% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $846M from the company's valuation, bringing the market cap to $4.34B at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its subsidiary, Health Ever Bio-Tech Co., Ltd., has been honored with the Innovation Gold Award for the development of its oral plant-derived investigational new drug BOTRESO^® for the treatment of benign prostatic hyperplasia (BPH) / lower urinary tract syndrome (LUTS), in the Pharmaceutical Category at the 2025 Taipei Biotech Awards, an event widely recognized as the “Oscars of Taiwan’s biotech industry.” The Gold Award, carrying a cash prize of more than US$26,000, was presented by Taipei City Mayor Wayne Chiang during the awards ceremony to recognize outstanding achievements in innovation and cross-disciplinary excellence in the biotech field.

(Vincent Chang, Associate Manager of Health Ever Bio-Tech Co., Ltd., accepts the 2025 Taipei Biotech Awards Innovation Gold Award on behalf of the company from Taipei City Mayor Wayne Chiang)

The award-winning product, BOTRESO^® holds multiple invention patents of pharmaceutical composition worldwide and has conducted four Phase III clinical trials (API-1) in the United States and Taiwan. Developed in Taiwan, BOTRESO^® is the first case of Taiwan-developed oral botanical new drug to receive U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval and advance into Phase III clinical trials. The new drug candidate (API-1) has completed the IND process and a New Drug Application (NDA) has been submitted to the U.S. FDA.

“Receiving the 2025 Taipei Biotech Awards Innovation Gold Award is a great honor and validates the years of research and development behind BOTRESO^® said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “This recognition highlights our leadership in plant-derived drug innovation and our commitment to bringing safe, effective therapies to patients worldwide. We will continue our efforts to expand our global presence and to deliver first-class botanical new drug to meet critical healthcare needs.”

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO^®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

FAQ

What award did Jyong Biotech (NASDAQ:MENS) receive at the 2025 Taipei Biotech Awards?

Jyong Biotech received the Innovation Gold Award in the Pharmaceutical Category, which included a cash prize of over $26,000, for their drug BOTRESO®.

What is BOTRESO® designed to treat?

BOTRESO® is designed to treat benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS).

What clinical trial milestones has BOTRESO® achieved?

BOTRESO® has completed four Phase III clinical trials in the United States and Taiwan, and has submitted a New Drug Application (NDA) to the U.S. FDA.

Why is BOTRESO® significant for Taiwan's biotech industry?

BOTRESO® is the first Taiwan-developed oral botanical drug to receive FDA Investigational New Drug approval and advance into Phase III clinical trials.

What is the current regulatory status of BOTRESO®?

BOTRESO® has completed the IND process and submitted a New Drug Application (NDA) to the U.S. FDA for review.